Eli Lilly (LLY) Income towards Parent Company (2009 - 2026)

Eli Lilly (LLY) posted Income towards Parent Company of $7.4 billion for Q1 2026, up 11.42% quarter-over-quarter from $6.6 billion in Q4 2025, and up 168.07% year-on-year from $2.8 billion in Q1 2025.

Eli Lilly (LLY) Income towards Parent Company (2009 - 2026) Analysis & Trends

Eli Lilly (LLY) has reported Income towards Parent Company for 17 consecutive years, with $7.4 billion the latest figure, recorded in Q1 2026.

  • Income towards Parent Company for Q1 2026 came in at $7.4 billion, up 168.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.3 billion (up 127.59% YoY), and the FY2025 annual result was $20.6 billion, up 94.9% from the prior year.
  • Income towards Parent Company was $7.4 billion for Q1 2026 at Eli Lilly, up from $6.6 billion in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $7.4 billion in Q1 2026 and troughed at -$57.4 million in Q3 2023.
  • Average Income towards Parent Company over 5 years is $2.9 billion, with a median of $2.2 billion recorded in 2023.
  • Year-over-year, Income towards Parent Company tumbled 103.95% in 2023 and jumped 1790.42% in 2024.
  • Over 5 years, Income towards Parent Company stood at $1.9 billion in 2022, then rose by 12.98% to $2.2 billion in 2023, then surged by 101.43% to $4.4 billion in 2024, then jumped by 50.52% to $6.6 billion in 2025, then advanced by 11.42% to $7.4 billion in 2026.
  • Per Business Quant data, the three most recent Income towards Parent Company figures were $7.4 billion in Q1 2026, $6.6 billion in Q4 2025, and $5.6 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 7.40 Bn
Dec 31, 2025 6.64 Bn
Sep 30, 2025 5.58 Bn
Jun 30, 2025 5.66 Bn
Mar 31, 2025 2.76 Bn
Dec 31, 2024 4.41 Bn
Sep 30, 2024 970.30 Mn
Jun 30, 2024 2.97 Bn
Mar 31, 2024 2.24 Bn
Dec 31, 2023 2.19 Bn
Sep 30, 2023 -57.40 Mn
Jun 30, 2023 1.76 Bn
Mar 31, 2023 1.34 Bn
Dec 31, 2022 1.94 Bn
Sep 30, 2022 1.45 Bn
Jun 30, 2022 952.50 Mn
Mar 31, 2022 1.90 Bn
Dec 31, 2021 1.73 Bn
Sep 30, 2021 1.11 Bn
Jun 30, 2021 1.39 Bn